Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Power Of Dialogue: Medical Innovation And Health Policy

The Power Of Dialogue: Medical Innovation And Health Policy The Power Of Dialogue: Medical Innovation And Health Policy Barbara J. Culliton, Contributing Editor, Health Affairs and Donald Kennedy, President Emeritus, Stanford University, Editor-in-Chief, Science The speed with which innovations in medical care are introduced into practice depends on many factors, including the investment in and success of biomedical research, the regulatory approval processes of the Food and Drug Administration (FDA), and third-party payers’ decisions to pay for new therapies. But little common dialogue links these activities in ways that could accelerate the movement of therapy from bench to bedside or overcome the challenges that face the U.S. system of delivering and financing care. An intellectual chasm exists between those who do innovative research and those who deliver it. Researchers and physician-scientists read different journals than their counterparts in health policy or economics; they attend different meetings; they speak different professional languages. For more than twenty-five years, Health Affairs has been one of the main journals through which the health policy community communicates. Now it is eager to add to that role, to foster a "conversation" in print and online to bring these separate communities together. Health Affairs’ founding editor, John Iglehart, describes it in shorthand as "NIH http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Health Affairs Health Affairs

The Power Of Dialogue: Medical Innovation And Health Policy

Health Affairs , Volume 27 (1): w24 – Jan 1, 2008

The Power Of Dialogue: Medical Innovation And Health Policy

Health Affairs , Volume 27 (1): w24 – Jan 1, 2008

Abstract

The Power Of Dialogue: Medical Innovation And Health Policy Barbara J. Culliton, Contributing Editor, Health Affairs and Donald Kennedy, President Emeritus, Stanford University, Editor-in-Chief, Science The speed with which innovations in medical care are introduced into practice depends on many factors, including the investment in and success of biomedical research, the regulatory approval processes of the Food and Drug Administration (FDA), and third-party payers’ decisions to pay for new therapies. But little common dialogue links these activities in ways that could accelerate the movement of therapy from bench to bedside or overcome the challenges that face the U.S. system of delivering and financing care. An intellectual chasm exists between those who do innovative research and those who deliver it. Researchers and physician-scientists read different journals than their counterparts in health policy or economics; they attend different meetings; they speak different professional languages. For more than twenty-five years, Health Affairs has been one of the main journals through which the health policy community communicates. Now it is eager to add to that role, to foster a "conversation" in print and online to bring these separate communities together. Health Affairs’ founding editor, John Iglehart, describes it in shorthand as "NIH

Loading next page...
 
/lp/health-affairs/the-power-of-dialogue-medical-innovation-and-health-policy-0CN0026cBm

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Health Affairs
Copyright
Copyright 2008 by Project HOPE: The People-to-People Health Foundation, Inc.
ISSN
0278-2715
eISSN
1544-5208
DOI
10.1377/hlthaff.27.1.w24
Publisher site
See Article on Publisher Site

Abstract

The Power Of Dialogue: Medical Innovation And Health Policy Barbara J. Culliton, Contributing Editor, Health Affairs and Donald Kennedy, President Emeritus, Stanford University, Editor-in-Chief, Science The speed with which innovations in medical care are introduced into practice depends on many factors, including the investment in and success of biomedical research, the regulatory approval processes of the Food and Drug Administration (FDA), and third-party payers’ decisions to pay for new therapies. But little common dialogue links these activities in ways that could accelerate the movement of therapy from bench to bedside or overcome the challenges that face the U.S. system of delivering and financing care. An intellectual chasm exists between those who do innovative research and those who deliver it. Researchers and physician-scientists read different journals than their counterparts in health policy or economics; they attend different meetings; they speak different professional languages. For more than twenty-five years, Health Affairs has been one of the main journals through which the health policy community communicates. Now it is eager to add to that role, to foster a "conversation" in print and online to bring these separate communities together. Health Affairs’ founding editor, John Iglehart, describes it in shorthand as "NIH

Journal

Health AffairsHealth Affairs

Published: Jan 1, 2008

There are no references for this article.